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Abstract 
The erythropoietin (Epo)-erythroferrone (ERFE)-hepcidin axis coordinates erythropoiesis and iron 
homeostasis. While mouse studies have established that Epo-induced ERFE production represses 
hepcidin synthesis by inhibiting hepatic BMP/SMAD signaling, evidence for the role of ERFE in 
humans is limited. To investigate the role of ERFE as a physiological erythroid regulator in 
humans, we conducted two studies: first, 24 males received six injections of saline (placebo), 
recombinant Epo (rhEpo) 20 UI kg-1 (micro-dose) or 50 UI kg-1 (low-dose). Second, we quantified 
ERFE in 22 subjects exposed to high altitude (3800 m) for 15 hours. In the first study, total 
hemoglobin mass (Hbmass) increased after low- but not after micro-dose injections, when compared 
to placebo. Serum ERFE levels were enhanced by rhEpo, remaining higher than after placebo for 48 
(micro-dose) or 72 hours (low-dose) post-injections. Conversely, hepcidin levels decreased when 
Epo and ERFE arose, before any changes in serum iron parameters occurred. In the second study, 
serum Epo and ERFE increased at high altitude. The present results demonstrate that in healthy 
humans ERFE responds to slightly increased Epo levels not associated with Hbmass expansion and 
down-regulates hepcidin in an apparently iron-independent way. Notably, ERFE flags micro-dose 
Epo, thus holding promise as novel anti-doping biomarker.  
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Introduction 
Erythropoiesis and iron metabolism are tightly linked and inadequate iron supply to developing 
erythrocytes results in anemia, a condition affecting a large segment of the world’s population. The 
coordination between erythropoietic activity and iron homeostasis is provided by hepcidin, which 
controls body iron balance by negatively regulating the activity of the iron exporter, ferroportin 1,2. 
Hepcidin expression is inhibited by iron deficiency and high erythropoietic activity 1,2, a response 
that increases iron availability to meet iron needs for hemoglobin (Hb) synthesis. Accordingly, we 
and others have demonstrated that recombinant human erythropoietin (rhEpo) administration to 
healthy humans is followed by a prompt hepcidin down-regulation 3-5. The identification and 
characterization of erythroferrone (ERFE), a hepcidin-inhibiting factor produced by erythroblasts in 
response to Epo, provided an additional link between erythropoietic activity and iron homeostasis 6. 
Mouse studies established that ERFE synthesized in response to Epo impairs hepcidin transcription 
by inhibiting hepatic BMP/SMAD signaling 6,7. The development of a validated assay for human 
ERFE allowed to show that ERFE is increased in patients with β-thalassemia and in response to 
blood donation or administration of high doses of rhEpo 8. Moreover, serum ERFE levels are 
elevated in patients with chronic kidney disease (CKD) treated with rhEpo 9 and in children affected 
by iron deficiency anemia 10. However, another study did not find increased ERFE levels in CKD 
patients 11. In addition, ERFE did not change in patients with reduced erythropoiesis caused by 
androgen deprivation therapy 12 or athletes exposed to altitude 13 and, unexpectedly, decreased in 
parallel with hepcidin in subjects experiencing Hbmass expansion due to altitude exposure 14. 
Therefore, the effect of accelerated erythropoiesis on ERFE in humans remains uncertain. Here, we 
tested the hypothesis that in healthy humans, ERFE is a physiologic erythroid regulator, i.e. 
responds to moderate erythropoietic stimulation, such as very low rhEpo doses or high altitude 
exposure.  
Methods 
Details of the methods are available in Supplementary material.  
Study design: for the rhEpo study, Hbmass, indices of iron homeostasis and hematological 
parameters were repeatedly measured in 24 healthy males receiving six injections (every 
second/third day) of saline (placebo), rhEpo 20 UI.kg-1 (micro-dose) or rhEpo 50 UI.kg-1 (low-dose) 
Written informed consent to participation in the study was provided by all subjects. The study 
(NCT03276910) was approved by the French ethics committee (CPP Est-III, EudraCT 2017-
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000375-82). For the high-altitude study, iron parameters were determined in 22 healthy subjects 
exposed to high altitude (3800 m) for 15 hours. Written informed consent to participation in the 
study was provided by all subjects. The study (NCT02778659) was approved by the French ethics 
committee (CPP Sud-Est-III, EudraCT 2015-004512-38).  
Results  
Three days after the last rhEpo injection, Hbmass was higher in subjects treated with rhEpo low-dose 
than those receiving placebo (Fig 1A). In contrast, treatment with rhEpo micro-doses did not induce 
significantly higher Hbmass levels in comparison to placebo treatment. Hbmass was not significantly 
altered following placebo treatment but nonetheless tended to decrease, possibly because of 
frequent blood sampling. Short treatment duration may otherwise explain the marginal change of 
Hbmass following rhEpo micro-doses. Unlike Hbmass, Hb concentration and hematocrit progressively 
increased with both rhEpo doses (Fig 2A and 2B). As expected, circulating Epo levels increased 
after each injection, but rapidly declined, in particular after micro-dose treatment (Fig 1B). ERFE 
levels showed a significant dose-related increase after each injection, remaining above placebo 
levels up to 48 (micro-dose) or 72 hours (low-dose) and decreasing thereafter (Fig 1C). Following 
low-dose rhEpo, ERFE reached levels similar to those found in patients with anemia induced by 
bleeding (see Supplementary material, Analyses section). The ERFE variation pattern mirrored that 
of serum Epo (Fig 3A). Conversely, serum hepcidin decreased when Epo and ERFE rose, 
independently of the dose, and remained low as long as Epo and ERFE were above baseline values 
(Fig 1D). Both ERFE and hepcidin returned to placebo levels one week after the last injection. 
Interestingly, there was no cumulative effect of repeated rhEpo injections on ERFE levels (Fig. 1C). 
Consistent with previous studies 3-5, the decrease in serum ferritin with rhEpo was progressive (Fig. 
2C). In contrast, transferrin saturation (Tfsat) was not significantly altered by rhEpo injections (Fig 
2D).  
We also found concomitant increases in Epo and ERFE in healthy subjects exposed to a high 
altitude condition associated with O2 saturation of 85 ± 3% (Fig 4A and 4B). The correlation 
between ERFE and serum Epo found at high altitude (Fig 3B) and with rhEpo treatment (Fig 3A) 
suggests that hypoxia-related signaling is not directly involved in ERFE induction, as previously 
shown in mice 6. ERFE tended to increase more with rhEpo micro-dose than with high altitude (P = 
0.22), whereas Epo increased less with micro-dose than with high altitude (P = 0.04) (result not 
shown). We speculate that the shorter time of exposure to elevated Epo levels at high altitude (15 h) 
versus micro-dose (24 h) may account for the observed trend. Tfsat, which was close to the level 
defining iron deficiency (<20%), did not change (Fig 4C). Consistent with the low Tfsat, hepcidin 
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concentration at sea level was below the detection limit in 15 subjects and was unchanged after 
exposure to high altitude in the subjects with detectable baseline values (Fig 4D). Lack of 
correlation between ERFE and hepcidin was previously found in CKD patients, in which increased 
ERFE levels were not accompanied by lower hepcidin 9. In line with a previous report showing 
unaltered iron availability and no signs of inflammation at high altitude,15 the inflammatory marker 
IL-6 was not affected by high altitude (1.28 ± 1.04 pg.mL-1, vs. 1.25 ± 0.9 pg.mL-1 at sea level), 
whereas ferritin concentration showed a small increase (from 125 ± 8 to 132 ± 7 ng.mL-1), 
nonetheless remaining within the normal range (Fig 4E). 
Discussion  
Recently, mouse studies have shown that acute rhEpo treatment down-regulates hepcidin in an 
ERFE-independent manner by decreasing serum iron and Tfsat 16,17. Moreover, the demonstration 
that rhEpo administration down-regulates hepcidin also in mice lacking ERFE 18 suggests that 
prolonged erythropoietic stimulation inhibits hepcidin expression in mice by depleting iron stores, 
whereas ERFE represents an acute regulator of stress erythropoiesis 18. Conversely, the present 
results show that in healthy humans ERFE responds even to low Epo levels which are not 
associated with Hbmass expansion, a functional marker of erythropoietic response 19. This conclusion 
is also supported by our findings in a physiological condition such as high-altitude hypoxia (Fig 4). 
Furthermore, our data showing no alterations in Tfsat and a progressive decrease in ferritin with 
repeated rhEpo injections are consistent with the view that ERFE may inhibit hepcidin transcription 
directly in the absence of changes in serum and liver iron 7. In fact, the ERFE-hepcidin axis was 
affected early, i.e. 24 hours after the first rhEpo injection, while other serum iron parameters were 
unchanged at that time, as t test analysis showed no difference in ferritin between groups at 24 and 
48 hours after the first injection (see Supplementary material, Statistical analysis section). However, 
it is well conceivable that under conditions of strong erythropoietic stimulation, such as in mice 
treated with high doses of rhEpo (8000 UI.kg-1) 16-18, increased iron consumption for erythropoiesis 
leads to iron depletion and hepcidin repression.  
The introduction of the Athlete’s Blood Passport (ABP) 20 has improved blood doping detection, 
although also the ABP has several limitations 21, in particular detecting micro-dose rhEpo doping 22. 
A study in which ERFE was measured in 6 subjects receiving intravenously or subcutaneously 
relatively high doses of rhEpo or analogs, using an assay different from the one used in this study 
did not suggest ERFE as a reliable marker for rhEpo doping 23, although (while our manuscript was 
under revision) the same group reported that a different ELISA assay was able to detect increased 
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ERFE levels in the same samples 24. Conversely, increased erythropoiesis induced by training did 
not affect ERFE and hepcidin levels in runners 25. Our results demonstrate that ERFE is sensitive 
enough to flag even micro-dose rhEpo, correlates with Epo levels (see Fig 3A and 3B) and has a 
detection window longer than that of Epo, thereby indicating that ERFE holds promise as a novel 
anti-doping biomarker for ABP implementation, although additional studies are required. In view of 
our results, ferritin or hepcidin could also be considered as potential micro-dose rhEpo biomarkers, 
however both factors may be confounded by iron supplementation, a legal practice commonly used 
by athletes. 
In summary, the present results demonstrate that in healthy humans ERFE is promptly enhanced in 
response to moderately increased Epo levels and represses hepcidin in an iron-independent way. 
ERFE determination may provide additional analytical support for the fight against doping.  
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FIGURE LEGENDS 
 
Figure 1. Effects of repeated administration of very low to low doses of recombinant human 
erythropoietin (rhEpo) on total hemoglobin mass, erythropoietin, erythroferrone and 
hepcidin. Panel A, total hemoglobin mass, determined at baseline (Pre) and 72 hours after the last 
of the six injections (Post) of placebo (n = 7), rhEpo 20 UI.kg-1 (micro-dose) (n = 7) or 50 UI.kg-1 
(low-dose) (n = 8). ANOVA indicates a significant time × treatment interaction (P = 0.049). 
*indicates a significant difference between rhEpo low-dose and placebo. Data are means ± SD. 
Individual Hbmass values are available in Supplementary Figure 1. 
Serum concentrations of erythropoietin (Epo, panel B), erythroferrone (ERFE, ln transformed, panel 
C, n = 7 for the placebo condition) and hepcidin (ln transformed, panel D) before, during and after 
six injections of placebo (n = 8), micro-dose (n = 8) or low-dose (n = 8) rhEpo. Vertical dotted lines 
indicate injections. Baselines are means from duplicate blood samples collected on separated days. 
Blood sampling was repeatedly performed at 24 hours (two occurrences), 48 hours (four 
occurrences) and 72 hours (two occurrences) after an injection. Additional samples were obtained at 
seven (7 d) and fourteen days (14 d) after the last injection. Numbers above the abscissa line (i.e. 
24, 48, 72, 7d and 14d) indicate these sampling times. Data are means ± SD. For each panel, 
inserted tables report estimated marginal means ± standard errors and P-values for the effect of the 
group (placebo, micro-dose, low-dose), the occurrence (i.e. the number of samples at 24 hours, 48 
hours, 72 hours, 7 days and 14 days, from 1 to 4) and the group × occurrence (G × O) interaction. 
Multiple comparisons between groups at 24 hours, 48 hours or 72 hours are reported in each table, * 
denoting a difference with placebo and ‡ a difference with micro-dose (see Supplementary material, 
Statistical analysis section).  
 
Figure 2. Effects of repeated administration of very low to low doses of recombinant human 
erythropoietin (rhEpo) on hematologic and iron parameters. Blood hemoglobin concentration 
(panel A), hematocrit (panel B), serum concentration of ferritin (ln transformed, panel C) and 
transferrin saturation (panel D) before, during and after six injections of placebo (n = 8), rhEpo 20 
UI.kg-1 (micro-dose) (n = 8) or 50 UI.kg-1 (low-dose) (n = 8). Vertical dotted lines indicate 
injections. Baselines are means from duplicate blood samples collected on separated days. Blood 
sampling was repeatedly performed at 24 hours (two occurrences), 48 hours (four occurrences) and 
72 hours (two occurrences) after an injection. Additional samples were obtained at seven (7 d) and 
fourteen days (14 d) after the last injection. Numbers above the abscissa line (i.e. 24, 48, 72, 7d and 
14d) indicate these sampling times. Data are means ± SD.  For each panel, inserted tables report 
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estimated marginal means ± standard errors and P-values for the effect of the group (placebo, 
micro-dose, low-dose), the occurrence (i.e. the number of samples at 24 h, 48 h, 72 h, 7 days and 14 
days, from 1 to 4) and the group × occurrence (G × O) interaction. Multiple comparisons between 
groups at 24 h, 48 h or 72 h are reported in each table, * denoting a difference with placebo and ‡ a 
difference with micro-dose (see Supplementary material, Statistical analysis section). 
Figure 3. Relationships between erythroferrone and erythropoietin with rhEpo and high 
altitude. Relationship between individual serum concentrations (ln transformed) of ERFE and Epo, 
before, during and after six injections of placebo, micro-dose or low-dose rhEpo in healthy subjects 
(panel A), and at sea level and after 15 hours of exposure to high altitude (3800 m) in healthy 
subjects (panel B). Regression equations, coefficients of determination and P values are reported on 
each panel. Relationships between hepcidin, Epo and ERFE during rhEpo injections are available in 
Supplementary Figure 2. 
Figure 4. Effects of acute exposure to high altitude. Individual serum concentrations and means ± 
SD of erythropoietin (Epo, panel A, n = 21), erythroferrone (ERFE, ln transformed, panel B, n = 
21), transferrin saturation (panel C, n = 22), hepcidin (ln transformed, panel D, n = 7) and ferritin 
(panel E, n = 22), at sea level and after 15 hours of exposure to high altitude (3800 m). Of note, out 
of 22 subjects, 15 subjects had sea-level hepcidin concentrations which were below the detection 
limit, therefore hepcidin statistical analysis was performed on 7 subjects. P values denote 
differences between sea level and high altitude. 
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Experimental design 
Study 1. Recombinant erythropoietin (rhEpo) treatment. 24 healthy non-athlete male subjects (age 
35 ± 9 years, height 177 ± 5 cm, body mass 74 ± 7 kg) gave written informed consent to participate 
in a randomized, double-blind, placebo-controlled study (NCT03276910) approved by the ethics 
committee (CPP Est-III, EudraCT 2017-000375-82). Only male subjects were included in this 
preliminary study to avoid the confounding effects that monthly blood loss in premenopausal 
women may have on iron parameters. After duplicate baseline collection on days -3 and 0, the 
subjects received six subcutaneous injections of saline (placebo, n=8) or rhEpo (epoietin alpha, 
Eprex®, Janssen-Cilag) at two different doses, i.e. 20 UI.kg-1 (micro-dose, n=8) or 50 UI.kg-1 (low-
dose, n=8) on days 0, 2, 4, 7, 9 and 11, according to doping protocols used by athletes. Venous 
blood (12 ml) was collected on days 1, 2, 3, 4, 7, 9, 11, 14, 18 and 25. These 10 samples were 
collected 24 hours (two occurrences), 48 hours (four occurrences), 72 hours (two occurrences), 7 
days (one occurrence) and 14 days (one occurrence) after an injection. All sampling and subsequent 
injections were performed in the morning at the same time for each subject. Hbmass was determined 
supine on the mornings on days -3 (Pre) and 14 (Post) via a carbon-monoxide rebreathing technique 
(OpCO, Detalo Instruments, Copenhagen), as described elsewhere 1. Carboxyhemoglobin levels 
were assessed with a co-oximeter ABL80-COOX-OSM (Radiometer, Copenhagen).  
Study 2. High-altitude exposure. 22 healthy subjects (eight women, age 36 ± 10 years, height 174 ± 
9 cm, body mass 69 ± 11 kg) gave written informed consent to participate in a study 
(NCT02778659) approved by the ethics committee (CPP Sud-Est-III, EudraCT 2015-004512-38) 2. 
Venous blood was collected supine upon wake up at 07:15 a.m. under the same temperature 
conditions at sea level and after 15 hours of exposure to hypobaric hypoxia (Aiguille du Midi, 3800 
m).  
Analyses 
Hb concentration (Hb) and hematocrit (Hct) were assessed on whole blood with a XN Series 
analyzer (Sysmex).  
Serum was stored at -80°C and ERFE levels were determined using an ELISA assay (Intrinsic 
LifeSci.) that detects ERFE in a standard range 0.16-10 ng.mL-1 and has been validated with 
clinically relevant human samples 3. To further validate this assay, we measured serum ERFE 
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concentration in 3 patients with anemia induced by bleeding (Hb concentration 96 ± 0.6 g.L-1). In 
line with previous findings showing a 3-4-fold increase of ERFE in blood donors 3, we found that 
ERFE levels were 3.7 ± 1.4 ng.mL-1 during anemia induced by bleeding, as compared to the mean 
concentration of 0.7 ± 1.2 ng.mL-1 determined at baseline in the healthy subjects examined in the 
present studies 1 and 2. Of note, ERFE after low-dose rhEpo reached levels of 3.6 ± 1.3 ng.mL-1, 
similar to those observed during anemia induced by bleeding.  
The other proteins were evaluated using commercially available ELISA for Epo (Quantikine, R&D 
Systems), IL-6 (high sensitivity, eBioscience), ferritin (Architect Ferritin, Abbott, IL). Serum iron 
was assessed by FerroZine colorimetry, transferrin was measured by nephelometry with N latex 
human transferrin and transferrin saturation (Tfsat) was calculated. Serum hepcidin was measured 
by SELDI-TOF mass spectrometry as described elsewhere 4.  
Statistical analysis 
Reported values are means ± SD. Statistics were performed with SPSS® (version 22.0, IBM Corp, 
Armonk, NY). In study 1, Hbmass data were analyzed using a two-way repeated measure ANOVA 
(time × treatment) with the Bonferroni’s method for pairwise comparisons. Mixed effects models 
were used to compare Epo, ERFE, hepcidin, Hb, Hct, ferritin, and Tfsat between groups at the 
different time points (study 1). Data were ln transformed to meet the conditions of applications of 
parametric tests, when needed. The group was included as a fixed factor, and baseline levels of 
these parameters were used as a covariate. We also tested the occurrence (one to four occurrences, 
depending on the time point considered) to assess the cumulative effect of repeated rhEpo 
injections, as well as the group × occurrence interaction. Since there was a strong cumulative effect 
on ferritin (see Fig 2C) preventing us to determine the onset of ferritin decline with the present 
statistical model, we also perform t tests on ferritin concentrations at 24 and 48 h after the first 
rhEpo injection. t tests indicated that ferritin levels in placebo subjects were similar to those 
observed in rhEpo-treated subjects with micro-dose (P values of 0.17 and 0.18 at 24 and 48 hours, 
respectively) or low-dose (P values of 0.39 and 0.29 at 24 and 48 hours, respectively). To evaluate 
the acute effect of rhEpo injection on ERFE, hepcidin and ferritin laboratory values, we calculated 
the area under the curve (AUC), by using the first three time points (i.e. baseline, 24 and 48 h after 
first injection). AUC were analyzed using a non-parametric Kruskal-Wallis test, indicating a 
significant rhEpo treatment effect for ERFE (placebo: 1.6 ± 1.4; Epo 20 UI.kg-1: 3.1 ± 3.6; Epo 50 
UI.kg-1: 4.0 ± 1.6; P = 0.03), but no treatment effect for hepcidin (placebo: 15.3 ± 8.9; Epo 20 
UI.kg-1: 7.7 ± 5.6; Epo 50 UI.kg-1: 6.3 ± 3.6; P = 0.11) or ferritin (placebo: 399 ± 242; Epo 20 
UI.kg-1: 259 ± 69; Epo 50 UI.kg-1: 313 ± 105; P = 0.37). In study 2, data were analyzed using a one-
S3 
 
way repeated measure ANOVA. For both studies, the relationship between two quantitative 
parameters was examined by linear regression. Unpaired t tests were performed on ln-transformed 
data to compare the effects of single rhEpo micro-dose injection (at 24 h) versus high-altitude 
exposure on ERFE and Epo increases. A P value of < .05 was considered significant. 
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Supplementary figure legends 
 
Supplementary Figure 1. Individual values of total hemoglobin mass, determined at baseline (Pre) 
and 72 hours after the last of the six injections (Post) of placebo (n = 7), rhEpo 20 UI.kg-1 (micro-
dose) (n = 7) or 50 UI.kg-1 (low-dose) (n = 8). Means, standard deviations and statistics are reported 
on Figure 1A.  
 
Supplementary Figure 2. Relationship between individual serum concentrations (ln transformed) 
of hepcidin plotted against Epo (panel A) and erythroferrone (ERFE, panel B) before, during and 
after six injections of placebo, micro-dose or low-dose rhEpo in healthy subjects. Regression 
equations, coefficients of determination and P values are y = -1.138x + 2.782, R² = 0.1025, 
P=0.0001(panel A), and y = -0.538x – 0.052, R² = 0.0721, P = 0.0001 (panel B). 
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